Reproductive Hormones During Sustained Administration of Kisspeptin

Last updated: September 9, 2024
Sponsor: Imperial College London
Overall Status: Active - Recruiting

Phase

N/A

Condition

Male Hormonal Deficiencies/abnormalities

Hypogonadism

Treatment

Kisspeptin 0.3

Kisspeptin 1.0

Kisspeptin 0.1

Clinical Study ID

NCT02081924
13/LO/1807
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

We want to find out what happens to reproductive hormone levels; Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH), testosterone and oestradiol when kisspeptin is administered to people for a period of 8 days each month, using either placebo (saline) or kisspeptin in doses of 0.1, 0.3 or 1.0 nmol/kg/hour.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Aged 18-60 years old

  • Ability to give informed consent

  • Secondary hypogonadism (or healthy participant)

Exclusion

Exclusion criteria:

  • anaemia

  • medical problems such as severe heart, kidney or liver disease

  • blood donation in the last three months or intention to donate blood within 3 monthsof the end of the study

  • needle phobia

  • Poor venous access

  • Active psychiatric illness

  • Severe allergies

  • Impaired ability to provide full consent to take part in the study

  • Current alcohol or illicit drug dependence

  • Current pregnancy or breast feeding

  • Plans to conceive within 3 months of starting the study (barrier contraception mustbe used during and for 3 months after the end of the study)

  • Arthritis or any impairment of hand coordination which would preclude using ahormone pump

Study Design

Total Participants: 76
Treatment Group(s): 4
Primary Treatment: Kisspeptin 0.3
Phase:
Study Start date:
April 02, 2014
Estimated Completion Date:
November 30, 2027

Study Description

Participants will be invited to have an initial baseline study to look at the hormone levels at regular intervals over the course of a day (8hours).

Following this, on a different day, volunteers will have an infusion of kisspeptin, which will be administered by a small pump to deliver the hormone into subcutaneous tissue (fatty tissue just below the skin surface). On day 1 of the pump infusion there will be another day of regular blood sampling for 8 hours. After this the kisspeptin pump will continue and the participants will return to the research unit on day 3 for a review and a single blood test. On day 5 the participants will have a review, a blood test and the kisspeptin pump will be changed. Kisspeptin infusion will continue and on Day 8 the participant will return for another 8 hour study. At the end of this the kisspeptin pump will be removed.

The above will be repeated using either placebo (saline) or kisspeptin in doses of 0.1, 0.3 or 1.0 nmol/kg/hour during the early follicular phase of 4 separate menstrual cycles.

Connect with a study center

  • Imperial College NHS Healthcare Trust

    London, W12 0NN
    United Kingdom

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.